封锁
毒性
抗体
双特异性抗体
免疫学
医学
抗原
免疫系统
T细胞
癌症研究
单克隆抗体
内科学
受体
作者
Elizabeth M. Burton,Hussein A. Tawbi
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2021-05-01
卷期号:11 (5): 1008-1010
被引量:10
标识
DOI:10.1158/2159-8290.cd-21-0257
摘要
Abstract Summary: Although combination anti–PD-1 and anti-CTLA4 mAbs have revolutionized outcomes for many cancers, their utility has been limited due to significant immune-related toxicities and the emergence of resistance. In this issue of Cancer Discovery, Dovedi and colleagues describe the development and preclinical testing of MEDI5752, a bispecific anti–PD-1/CTLA4 antibody designed to optimize therapeutic response by maximizing CTLA4 blockade on antigen-experienced T cells, thereby increasing efficacy and potentially minimizing toxicity. See related article by Dovedi et al., p. 1100.
科研通智能强力驱动
Strongly Powered by AbleSci AI